Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) under the GlaxoSmithKline Deferred Annual Bonus Plan (DABP).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the fair market value of American Depositary Shares (ADS) used for tax withholding, which was $46.73 per ADS.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details specific share withholdings to meet tax liabilities following the vesting of pre-tax awards granted in 2012 on March 9, 2015.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) regarding insider transactions.
Important Facts for Investors
- Transaction Type: Withholding of ADSs to meet tax liabilities upon vesting of 2012 DABP awards.
- Share Price: ADSs were valued at $46.73 for the withholding calculation.
- Directors Involved:
- Dr. M. Slaoui (Executive Director): 11,137 ADSs withheld.
- Mr. W. Louv (PDMR): 3,009 ADSs withheld.
- Mr. D. Troy (PDMR): 4,517 ADSs withheld.
- Notification Date: Transactions were advised on March 10, 2015, and the report was signed on March 11, 2015.